NCT02027753 - Efficacy and Safety of Insulin Glargine in Patients With Type 2 Diabetes With Inadequate Control on DPP-4 Inhibitor Therapy | Biotech Hunter

Enrollment

109

Participants

Timeline

Start Date

December 31, 2013

Primary Completion Date

April 30, 2015

Study Completion Date

April 30, 2015

Conditions

Diabetes Mellitus, Type 2

Interventions

DRUG

INSULIN GLARGINE

Pharmaceutical form: solution Route of administration: subcutaneous

DRUG

Metformin

Pharmaceutical form: tablet Route of administration: oral

DRUG

DPP-4 inhibitor

Pharmaceutical form: tablet Route of administration: oral

DRUG

Sulphonylurea

Pharmaceutical form: tablet Route of administration: oral

Trial Locations (1)

Sanofi-Aventis Administrative Office, Seoul